IFAM
VRDN icon

Institutional & Family Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Institutional & Family Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$234 Hold
18
– – ﹤0.01% 729
2024
Q1 		$315 Hold
18
– – ﹤0.01% 711
2023
Q4 		$392 Hold
18
– – ﹤0.01% 680
2023
Q3 		$276 Buy
18
+8
+80% +$153 ﹤0.01% 690
2023
Q2 		$238 Hold
10
– – ﹤0.01% 725
2023
Q1 		$254 Buy
+10
New +$321 ﹤0.01% 706

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Institutional & Family Asset Management's VRDN Position: Q2 2024 in Review

Institutional & Family Asset Management held its Viridian Therapeutics (VRDN) position steady in Q2 2024 at 18 shares worth $234. The position accounts for ﹤0.01% of the portfolio, ranked #729.

Institutional & Family Asset Management first reported a position in VRDN in Q1 2023 and has held it in 6 quarters since. The position peaked at $392 in Q4 2023. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Institutional & Family Asset Management held 18 shares of Viridian Therapeutics worth $234 as of Q2 2024.
  • Institutional & Family Asset Management left its Viridian Therapeutics share count unchanged in Q2 2024.
  • Viridian Therapeutics made up ﹤0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #729 holding.
  • Institutional & Family Asset Management first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 6 quarters since.
  • Institutional & Family Asset Management's Viridian Therapeutics position peaked at $392 in Q4 2023.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.